Axsome Therapeutics Inc

Medical Science Liaison

Saudi Arabia

Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biopharmaceutical, Pharmaceuticals, BiotechnologyIndustries

Medical Science Liaison (MSL)

Employment Type: Full time

Company Overview:

PTC Therapeutics is a global commercial biopharmaceutical company. For over 25 years, our team has been deeply committed to a unified purpose: Extending life’s moments for children and adults living with a rare disease.

At PTC, we cultivate an inclusive culture where everyone feels valued, respected, and empowered. We welcome candidates from all backgrounds to join our team, fostering a strong sense of belonging.

Website: www.ptcbio.com

Position Overview:

PTC is an established global biopharmaceutical company that delivers transformative therapies for people living with rare diseases. For over 25 years, we have been harnessing our scientific platforms to create new therapies that address the underlying cause of the disease and deliver on our promise to create more moments for those who count on us.

We are on an exciting journey working to change patients’ lives every single day. We are motivated by our patients and the drive for them to have more moments with their families, made possible in part by our research and therapies.

The Medical Science Liaison (MSL) is a field-based position within Medical Affairs. This role supports disease diagnosis, diagnostic methods, and strategic initiatives to facilitate early, accurate diagnosis across all programs of the PTC portfolio within the assigned country. The MSL supports and represents PTC and its products with key opinion leaders (KOLs), clinicians, academic institutions, and professional organizations. The MSL addresses the specific needs of these clients by responding to unsolicited requests for information about PTC Therapeutics' marketed products and treatment areas promptly and accurately.

Clinical expertise for disease state, clinical presentation, and differential diagnosis of the diseases of interest in PTC’s portfolio will allow the MSL to evaluate and address regional diagnosis gaps. The MSL will develop strategic and innovative diagnosis initiatives within their country to complement the PTC portfolio, supporting PTC programs from clinical trial through commercialization. The MSL will partner with the clinical science and diagnostics function, working in a matrix organization, to support early disease recognition and diagnosis by healthcare providers. As the clinical and medical expert on the company’s products, the MSL builds long-term relationships and establishes rapport with clinicians in hospitals, clinics, and academic centers through highly scientific product and disease state discussions that support or expand current therapeutic concepts and ensures safe and effective utilization of products. The incumbent is also a resource to company management regarding market dynamics, business development, and client feedback.

Responsibilities:

  • Attends national and regional medical meetings and symposia as a representative of PTC and engages in discussions with attendees as appropriate.
  • Attends scientific sessions and poster presentations, gathers information, and summarizes findings.
  • Cultivates professional relationships from contacts made at meetings when possible and appropriate.
  • Delivers, and may develop/design, fair-balanced and objective clinical and scientific presentations to healthcare professionals (HCPs), payors, and patient organizations in response to unsolicited requests for information on the use of company products.
  • Identifies and trains speakers for advisory boards, symposia, and educational programs using regulatory-approved materials, slide sets, abstracts, posters, etc.
  • Identifies, organizes, and carries out regional medical initiatives, such as advisory boards, as needed.
  • Provides input to management regarding alternative therapies, business development opportunities/risks, and client feedback.
  • Establishes, manages, and maintains successful relations with relevant health authorities.

Requirements:

(No specific requirements were provided in the original text.)

Application Instructions:

(No specific application instructions were provided in the original text.)

Skills

Medical Affairs
Disease Diagnosis
Clinical Expertise
KOL Engagement
Biopharmaceutical Products
Therapeutic Areas
Scientific Platforms
Rare Diseases

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI